艾米利克斯制药公司美国存托凭证招股说明书（2026年8月18日版）

Shares of common stock We are offeringshares of our common stock, par value $0.0001 per share. Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol “AMLX.” On August18,2026, the closing price of our common stock, as reported on Nasdaq, was $35.11 per share. Investing in our securities involves significant risks that are described in the “RISK FACTORS”section beginning on page S-7 of this prospectus supplement and page 8 of the accompanyingprospectus, and in the other documents that are incorporated by reference herein. You should read theentire prospectus supplement and the accompanying prospectus, including any informationincorporated by reference herein or therein, carefully, before you make your investment decision. We are a smaller reporting company as defined under Rule 405 of the Securities Act of 1933, as amended, or the SecuritiesAct, and, as such, are subject to certain reduced public company reporting requirements. See “Prospectus Supplement Summary—Implications of Being a Smaller Reporting Company” on page S-4 of this prospectus supplement. Per shareTotalPublic offering price$$Underwriting discounts and commissions(1)$$Proceeds, before expenses, to us$$ (1)We have agreed to reimburse the underwriters for certain expenses. See “Underwriting” beginning on pageS-20of thisprospectus supplement for additional information regarding the compensation payable to the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to an additionalshares of ourcommon stock at the public offering price less the underwriting discounts and commissions. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapprovedof these securities or determined if this prospectus supplement is truthful or complete. Any representation to thecontrary is a criminal offense. The underwriters expect to deliver the shares of common stock against payment on or about August, 2026. MorganStanleyGuggenheimSecurities LifeSciCapital Prospectus Supplement dated August, 2026 Table of Contents Table of Contents Prospectus Supplement ABOUT THIS PROSPECTUS SUPPLEMENTPROSPECTUS SUPPLEMENT SUMMARYTHE OFFERINGRISK FACTORSSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSUSE OF PROCEEDSDIVIDEND POLICYDILUTIONCERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONSUNDERWRITINGLEGAL MATTERSEXPERTSWHERE YOU CAN FIND MORE INFORMATIONINCORPORATION OF CERTAIN INFORMATION BY REFERENCE Prospectus About this ProspectusSpecial Note Regarding Forward-Looking StatementsThe CompanyWhere You Can Find More InformationIncorporation By ReferenceRisk FactorsUse of ProceedsDescription of Capital StockDescription of Debt SecuritiesDescription of WarrantsDescription of UnitsPlan of DistributionLegal MattersExperts Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This document has two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of common stock.The second part is the accompanying prospectus which provides more general information, some of which may not apply to this offering. Theinformation included or incorporated by reference in this prospectus supplement also adds to, updates and changes information contained orincorporated by reference in the accompanying prospectus. If information included or incorporated by reference in this prospectus supplement isinconsistent with the accompanying prospectus or the information incorporated by reference therein, then this prospectus supplement or the informationincorporated by reference in this prospectus supplement will apply and will supersede the information in the accompanying prospectus and thedocuments incorporated by reference therein. This prospectus supplement is part of our shelf registration statement on Form S-3 (File No.333-293956) that we filed with the Securities andExchange Commission, or the SEC, on March3, 2026, using a “shelf” registration process as a “well-known seasoned issuer” as defined in Rule 405 ofthe Securities Act of 1933, as amended, or the Securities Act, which became automatically effective upon filing. Under this shelf registration process, wemay from time to time offer and sell any combination of the securities described in the accompanying prospectus, of which this offering is a part. You should rely only on the information contained or incorporated by reference in this prospectus supplement, the accompanyingprospectus and any free writing prospectus prepared by us or on our behalf. We have not, and the underwriters have not, authorized any otherperson to provide you with information different from that contained in this prospectus supplement and the accompanying prospectus orincorporated by reference in this prospectus supplement and the accompanying prospectus. If anyone provides you with different orinconsistent information, you should not rely on it. We are not, and the underwriters are not, making an